Progress not panacea: vancomycin powder efficacy and dose evaluated in an in vivo mouse model of spine implant infection

Intrawound vancomycin powder (VP) has been rapidly adopted in spine surgery with apparent benefit demonstrated in limited, retrospective studies. Randomized trials, basic science, and dose response studies are scarce. This study aims to test the efficacy and dose effect of VP over an extended time c...

Full description

Saved in:
Bibliographic Details
Published in:The spine journal 2020-06, Vol.20 (6), p.973-980
Main Authors: Park, Howard Y., Hegde, Vishal, Zoller, Stephen D., Sheppard, William, Hamad, Christopher, Smith, Ryan A., Sprague, Marina M., Proal, Joshua D., Hoang, John, Loftin, Amanda, Blumstein, Gideon, Burke, Zachary, Cevallos, Nicolas, Scaduto, Anthony A., Bernthal, Nicholas M.
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - therapeutic use
Biofilm
Infection
Mice
Powders
Retrospective Studies
Surgical site infection
Surgical Wound Infection - drug therapy
Vancomycin - therapeutic use
Vancomycin powder
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intrawound vancomycin powder (VP) has been rapidly adopted in spine surgery with apparent benefit demonstrated in limited, retrospective studies. Randomized trials, basic science, and dose response studies are scarce. This study aims to test the efficacy and dose effect of VP over an extended time course within a randomized, controlled in vivo animal experiment. Randomized controlled experiment utilizing a mouse model of spine implant infection with treatment groups receiving vancomycin powder following bacterial inoculation. Utilizing a mouse model of spine implant infection with bioluminescent Staphylococcus aureus, 24 mice were randomized into 3 groups: 10 infected mice with VP treatment (+VP), 10 infected mice without VP treatment (No-VP), and 4 sterile controls (SC). Four milligrams of VP (mouse equivalent of 1 g in a human) were administered before wound closure. Bioluminescence imaging was performed over 5 weeks to quantify bacterial burden. Electron microscopy (EM), bacterial colonization assays (Live/Dead) staining, and colony forming units (CFU) analyses were completed. A second dosing experiment was completed with 34 mice randomized into 4 groups: control, 2 mg, 4 mg, and 8 mg groups. The (+VP) treatment group exhibited significantly lower bacterial loads compared to the control (No-VP) group, (p
ISSN:1529-9430
1878-1632
DOI:10.1016/j.spinee.2019.12.007